Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

BeOne Medicines (BEIGF) Debt to Equity (2016 - 2025)

BeOne Medicines (BEIGF) has disclosed Debt to Equity for 11 consecutive years, with $0.23 as the latest value for Q4 2025.

  • Quarterly Debt to Equity fell 23.5% to $0.23 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $0.23 through Dec 2025, down 23.5% year-over-year, with the annual reading at $0.23 for FY2025, 23.5% down from the prior year.
  • Debt to Equity for Q4 2025 was $0.23 at BeOne Medicines, down from $0.4 in the prior quarter.
  • The five-year high for Debt to Equity was $0.4 in Q3 2025, with the low at $0.05 in Q4 2022.
  • Average Debt to Equity over 5 years is $0.2, with a median of $0.18 recorded in 2021.
  • The sharpest move saw Debt to Equity crashed 53.53% in 2022, then skyrocketed 424.93% in 2023.
  • Over 5 years, Debt to Equity stood at $0.1 in 2021, then plummeted by 53.53% to $0.05 in 2022, then surged by 424.93% to $0.25 in 2023, then rose by 21.97% to $0.31 in 2024, then fell by 23.5% to $0.23 in 2025.
  • According to Business Quant data, Debt to Equity over the past three periods came in at $0.23, $0.4, and $0.25 for Q4 2025, Q3 2025, and Q2 2025 respectively.